tandem diabetes care inc - TNDM
TNDM
Close Chg Chg %
22.26 0.48 2.16%
Closed Market
22.74
+0.48 (2.16%)
Volume: 1.59M
Last Updated:
May 8, 2025, 4:00 PM EDT
Company Overview: tandem diabetes care inc - TNDM
TNDM Key Data
| Open $22.26 | Day Range 22.24 - 23.29 |
| 52 Week Range 15.75 - 53.69 | Market Cap $1.48B |
| Shares Outstanding 66.61M | Public Float 66.06M |
| Beta 1.48 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.78 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.77M |
TNDM Performance
| 1 Week | 5.87% | ||
| 1 Month | 33.29% | ||
| 3 Months | -37.01% | ||
| 1 Year | -48.74% | ||
| 5 Years | -74.09% |
TNDM Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
25
Full Ratings ➔
About tandem diabetes care inc - TNDM
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
TNDM At a Glance
Tandem Diabetes Care, Inc.
12400 High Bluff Drive
San Diego, California 92130
| Phone | 1-858-366-6900 | Revenue | 940.20M | |
| Industry | Medical Specialties | Net Income | -96,025,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 25.743% | |
| Fiscal Year-end | 12 / 2025 | Employees | 2,650 | |
| View SEC Filings |
TNDM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.507 |
| Price to Book Ratio | 9.072 |
| Price to Cash Flow Ratio | 97.319 |
| Enterprise Value to EBITDA | -28.996 |
| Enterprise Value to Sales | 2.545 |
| Total Debt to Enterprise Value | 0.198 |
TNDM Efficiency
| Revenue/Employee | 354,793.585 |
| Income Per Employee | -36,235.849 |
| Receivables Turnover | 8.205 |
| Total Asset Turnover | 0.979 |
TNDM Liquidity
| Current Ratio | 2.933 |
| Quick Ratio | 2.327 |
| Cash Ratio | 1.774 |
TNDM Profitability
| Gross Margin | 50.507 |
| Operating Margin | -10.543 |
| Pretax Margin | -9.771 |
| Net Margin | -10.213 |
| Return on Assets | -10.001 |
| Return on Equity | -33.30 |
| Return on Total Capital | -13.035 |
| Return on Invested Capital | -13.816 |
TNDM Capital Structure
| Total Debt to Total Equity | 179.996 |
| Total Debt to Total Capital | 64.285 |
| Total Debt to Total Assets | 48.939 |
| Long-Term Debt to Equity | 157.617 |
| Long-Term Debt to Total Capital | 56.293 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Tandem Diabetes Care Inc - TNDM
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 702.80M | 801.22M | 747.72M | 940.20M | |
Sales Growth
| +40.89% | +14.00% | -6.68% | +25.74% | |
Cost of Goods Sold (COGS) incl D&A
| 338.23M | 400.56M | 393.84M | 465.34M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 13.85M | 14.33M | 15.71M | 16.61M | |
Depreciation
| 11.64M | 12.33M | 13.81M | 14.71M | |
Amortization of Intangibles
| 2.20M | 2.00M | 1.90M | 1.90M | |
COGS Growth
| +38.31% | +18.43% | -1.68% | +18.15% | |
Gross Income
| 364.57M | 400.66M | 353.88M | 474.87M | |
Gross Income Growth
| +43.37% | +9.90% | -11.68% | +34.19% | |
Gross Profit Margin
| +51.87% | +50.01% | +47.33% | +50.51% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 341.92M | 462.46M | 508.36M | 573.99M | |
Research & Development
| 80.41M | 126.78M | 155.85M | 184.17M | |
Other SG&A
| 261.51M | 335.68M | 352.50M | 389.82M | |
SGA Growth
| +30.38% | +35.26% | +9.92% | +12.91% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 1.39M | 30.89M | 78.75M | 1.27M | |
EBIT after Unusual Expense
| 21.27M | (92.70M) | (233.23M) | (100.39M) | |
Non Operating Income/Expense
| 674.00K | 6.06M | 22.86M | 15.94M | |
Non-Operating Interest Income
| 674.00K | 6.06M | 22.86M | 17.99M | |
Equity in Earnings of Affiliates
| - | - | - | (2.05M) | - |
Interest Expense
| 6.04M | 6.21M | 9.88M | 7.42M | |
Interest Expense Growth
| -52.83% | +2.78% | +59.18% | -24.96% | |
Gross Interest Expense
| 6.04M | 6.21M | 9.88M | 7.42M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 15.90M | (92.85M) | (220.25M) | (91.87M) | |
Pretax Income Growth
| +143.83% | -683.94% | -137.21% | +58.29% | |
Pretax Margin
| +2.26% | -11.59% | -29.46% | -9.77% | |
Income Tax
| 335.00K | 1.74M | 2.36M | 4.16M | |
Income Tax - Current - Domestic
| 174.00K | 1.44M | 653.00K | 1.78M | |
Income Tax - Current - Foreign
| 161.00K | 298.00K | 1.70M | 2.38M | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | (2.05M) | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 15.57M | (94.59M) | (222.61M) | (96.03M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 15.57M | (94.59M) | (222.61M) | (96.03M) | |
Net Income Growth
| +145.27% | -707.70% | -135.33% | +56.86% | |
Net Margin Growth
| +2.21% | -11.81% | -29.77% | -10.21% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 15.57M | (94.59M) | (222.61M) | (96.03M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 15.57M | (94.59M) | (222.61M) | (96.03M) | |
EPS (Basic)
| 0.2471 | -1.4747 | -3.4264 | -1.4671 | |
EPS (Basic) Growth
| +143.84% | -696.80% | -132.35% | +57.18% | |
Basic Shares Outstanding
| 63.00M | 64.15M | 64.97M | 65.45M | |
EPS (Diluted)
| 0.2419 | -1.4747 | -3.4264 | -1.4671 | |
EPS (Diluted) Growth
| +142.91% | -709.63% | -132.35% | +57.18% | |
Diluted Shares Outstanding
| 64.35M | 64.15M | 64.97M | 65.45M | |
EBITDA
| 36.50M | (47.48M) | (138.76M) | (82.52M) | |
EBITDA Growth
| +1,363.43% | -230.09% | -192.27% | +40.53% | |
EBITDA Margin
| +5.19% | -5.93% | -18.56% | -8.78% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 39.238 | |
| Number of Ratings | 25 | Current Quarters Estimate | -0.405 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | -1.966 | |
| Last Quarter’s Earnings | -1.97 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.47 | Next Fiscal Year Estimate | -0.678 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 15 | 15 | 18 | 16 |
| Mean Estimate | -0.40 | -0.28 | -1.97 | -0.68 |
| High Estimates | -0.26 | -0.15 | -1.07 | 0.12 |
| Low Estimate | -0.57 | -0.44 | -2.84 | -1.41 |
| Coefficient of Variance | -18.46 | -29.17 | -35.05 | -50.99 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 11 | 11 | 13 |
| OVERWEIGHT | 2 | 3 | 2 |
| HOLD | 11 | 10 | 8 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Tandem Diabetes Care Inc - TNDM
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Tandem Diabetes Care Inc - TNDM
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 21, 2025 | Rick Carpenter Chief Technology Officer | 1,218 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Rick Carpenter Chief Technology Officer | 16,392 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.17 per share | 314,234.64 |
| Mar 21, 2025 | Rick Carpenter Chief Technology Officer | 16,538 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Mark Novara EVP & CHIEF COMMERCIAL OFFICER | 51,902 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Mark Novara EVP & CHIEF COMMERCIAL OFFICER | 24,134 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.17 per share | 462,648.78 |
| Mar 21, 2025 | Mark Novara EVP & CHIEF COMMERCIAL OFFICER | 26,873 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 12, 2025 | Jean-Claude Kyrillos EVP & Chief Operating Officer | 10,538 | Open market or private purchase of non-derivative security Non-derivative transaction at $18.12 per share | 190,948.56 |
| Feb 28, 2025 | Leigh A. Vosseller EVP & CHIEF FINANCIAL OFFICER | 27,225 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.34 per share | 907,681.50 |
| Feb 28, 2025 | Susan M. Morrison EVP & Chief Admin. Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Susan M. Morrison EVP & Chief Admin. Officer | 27,693 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Leigh A. Vosseller EVP & CHIEF FINANCIAL OFFICER | 29,252 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Leigh A. Vosseller EVP & CHIEF FINANCIAL OFFICER | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | John F. Sheridan PRESIDENT & CEO; Director | 66,389 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Susan M. Morrison EVP & Chief Admin. Officer | 31,189 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.34 per share | 1,039,841.26 |
| Feb 28, 2025 | Leigh A. Vosseller EVP & CHIEF FINANCIAL OFFICER | 23,729 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.34 per share | 791,124.86 |
| Feb 28, 2025 | Susan M. Morrison EVP & Chief Admin. Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | John F. Sheridan PRESIDENT & CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | John F. Sheridan PRESIDENT & CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | John F. Sheridan PRESIDENT & CEO; Director | 79,009 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.34 per share | 2,634,160.06 |
| Feb 28, 2025 | John F. Sheridan PRESIDENT & CEO; Director | 89,017 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |